Please assess the completion status of the following clinical trial:

Trial Title: A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Histologically or cytologically confirmed adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease~* Age ≥ 18 years~* Adequate left ventricular function at study entry, defined as an Left Ventricular Ejection Fraction (LVEF) \> 50% by either Multi Gated Acquisition(MUGA) scan or Electrocardiogram (ECHO)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Ability and willingness to comply with study and follow-up procedures~Exclusion Criteria:~* Unknown HER2 status or known HER2-positive status~* Prior chemotherapy for locally recurrent or metastatic disease~* Prior hormonal therapy within 2 weeks prior to Day 1~* Prior adjuvant or neoadjuvant taxane chemotherapy within 12 months prior to Day 1~* Prior adjuvant or neoadjuvant non-taxane chemotherapy within 6 months prior to Day 1~* For patients who have received recent radiotherapy, ongoing Grade ≥ 3 acute toxicity~* Patients with brain metastasis on full dose anticoagulation therapy~* Life expectancy of \< 12 weeks~* Current, recent (within 4 weeks of Day 1), or planned participation in an experimental drug study~* Inadequate organ function within 28 days prior to Day 1~* Untreated abnormal thyroid function tests~* Uncontrolled serious medical or psychiatric illness~* Active infection requiring IV antibiotics at enrollment or randomization~* History of other malignancies within 5 years prior to Day 1 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix~* Inadequately controlled hypertension~* Prior history of hypertensive crisis or hypertensive encephalopathy~* New York Heart Association (NYHA) Class II or greater CHF~* History of myocardial infarction or unstable angina within 12 months prior to Day 1~* History of stroke or transient ischemic attack within 12 months prior to Day 1~* Known central nervous system (CNS) disease except for treated brain metastasis~* Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1~* History of hemoptysis within 1 month prior to Day 1~* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study~* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1~* History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1~* Serious, non-healing wound, active ulcer, or untreated bone fracture~* Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0 at screening~* Known hypersensitivity to any component of bevacizumab or sunitinib~* Pregnancy (positive pregnancy test) or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy